Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ChemImage, a provider of chemical and biological imaging technology solutions, has formed a strategic research partnership with Next Breath, a contract research organization to further validate ChemImage's Raman Chemical Imaging for bioequivalence applications for nasal spray suspensions.
Subscribe to our email newsletter
ChemImage will be partnering with Next Breath to compare optical microscopy to Raman Chemical Imaging, specifically ChemImage’s Falcon II wide-field Raman chemical imaging system.
The Falcon II enables drug manufacturers to perform chemical imaging of particles in droplets to distinguish the identity, particle size distribution of drug and other substances, aggregation, and the correlation about the location of the material in the formulation – something drug makers have been unable to achieve in the past with standard optical microscopy as part of bioequivalence testing, said ChemImage.
ChemImage’s Falcon II is currently available for sale across international markets. ChemImage also offers imaging lab services for companies interested in expediting bioequivalence testing. The company expects the additional validation testing to be conducted in 2009 and 2010.
Ryan Priore, senior scientist of ChemImage, said: “We are proud to partner with Next Breath because our goal at ChemImage is to validate our bioequivalence testing methodology.
“Pharmaceutical companies, particularly generic drug manufacturers focused on nasal spray suspensions, are looking to improve their time-to-market through the use of better imaging technology. The potential payoff is a faster, more accurate and safe way to bring the drug to market.”